Study the Efficacy and Safety of VAY736 and CFZ533 in SLE Patients
| 対象疾患 | Systemic Lupus Erythematosus |
|---|---|
| 相 | 第2相 |
| スポンサー | Novartis Pharmaceuticals |
| ステータス | 完了 |
| 参加者数 | 107 名 |
| 介入（薬剤） | VAY736, VAY736 Placebo, CFZ533, CFZ533 Placebo |
| 開始日 | 2018年12月19日 |
| 完了日 | 2022年7月27日 |
| 結果公開日 | 2024年6月6日 |
概要
This study is designed to evaluate the safety, tolerability, pharmacokinetics and therapeutic efficacy of treatment with either VAY736 (ianalumab) or CFZ533 (iscalimab) in patients with systemic lupus erythematosus (SLE) to enable further development of these compounds as treatment in this disease population
Percentage of Participants With SLE Responder Index (SRI)-4 Response Status at Week 29 With Reduced Steroid Dose Maintained Between Weeks 17 and 29
| Cohort 1 VAY736 | 15 Participants |
|---|---|
| Cohort 1 VAY736 Placebo | 3 Participants |
| Cohort 2 CFZ533 | 8 Participants |
| Cohort 2 CFZ533 Placebo | 6 Participants |
BENITIONS で見る ClinicalTrials.gov の原文を見る
同じ疾患の他の治験
- Clinical Study to Investigate the Biological Activity, Safety, Tolerability, and Pharmacok — Viatris Innovation GmbH
- Efficacy and Safety of Four Doses of Cenerimod Compared to Placebo in Adult Subjects With — Viatris Innovation GmbH
- A Study to Evaluate the Efficacy and Safety of Obinutuzumab in Participants With ISN/RPS 2 — Hoffmann-La Roche
- Peer i-Coaching for Activated Self-Management Optimization in Adolescents and Young Adults — Duke University
- Reducing Disparities in Medication Adherence in SLE — Duke University
- Using the Cholinergic Anti-Inflammatory Pathway to Treat Systemic Lupus Musculoskeletal Pa — Northwell Health